Eli Lilly stock has surged over the past few years, and at around US$1,235 per share today, investors face a clear tension between strong price momentum and mixed valuation signals. The Discounted Cash Flow (DCF) intrinsic value suggests upside, while market multiples look rich.

• Eli Lilly has delivered a very large 5 year return of about 4.5x, which puts extra focus on whether the current price still leaves any margin of safety.
• Expectations around continued demand for Eli Lilly's obesity and diabetes treatments can support optimism on cash flows, while regulatory and pricing pressures highlighted in recent coverage remain a key risk to how much of that cash ultimately reaches shareholders.
• On Simply Wall St's wider checks, Eli Lilly only passes 2 out of 6 valuation tests. This leans more toward expensive than clearly cheap, despite the DCF reading suggesting the stock trades about 22.3% below intrinsic value.

For investors, the debate is whether Eli Lilly's recent run and rich market multiples already price in most of that intrinsic value upside, or if the DCF view will prove closer to the mark.

Does Eli Lilly Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Eli Lilly is worth based on the cash it can return to shareholders over time. For Eli Lilly, the model starts with latest twelve month free cash flow of about $8.6b, then assumes cash flows continue to grow rather than shrink or plateau, which fits a company that is still investing heavily behind key franchises.

On those assumptions, the DCF model points to an intrinsic value of about $1,591 per share, compared with a current price of around $1,235, which implies the stock screens roughly 22.3% undervalued on this metric. Because recent news includes strong GLP-1 revenue momentum and raised guidance, the DCF outcome suggests the market price may not fully reflect the cash flow implied by that operational performance. On the DCF numbers alone, Eli Lilly appears undervalued relative to where the stock is currently trading.

Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 22.3%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.

Has Eli Lilly Run Too Far on Earnings?

P/E is usually a straightforward way to compare mature, profitable drug makers like Eli Lilly, because it ties the share price directly to reported earnings. At around 43.6x, Eli Lilly’s current P/E is far above the Pharmaceuticals industry average of 15.5x and also ahead of the broader peer group average of 25.2x, so you are clearly paying a premium to own the stock.

Simply Wall St’s fair P/E estimate for Eli Lilly is 39.2x, based on its growth profile, margins, size and risk factors. That is below the current 43.6x, which implies investors are paying more than this tailored benchmark would suggest is reasonable. The gap is not extreme, but it does point to Eli Lilly appearing overvalued on earnings compared with both its sector and the model’s fair multiple.

Overall, Eli Lilly screens as overvalued on the P/E multiple, with the market pricing in a premium above both peers and the modelled fair ratio.

The Eli Lilly Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Eli Lilly pick up where this valuation puzzle leaves off by spelling out which assumptions about Eli Lilly's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than its current price. These narratives sit on Simply Wall St's Community page. Each one sets out a fair value view as a thesis about the business that can be revisited over time, rather than a one off snapshot.

Eli Lilly community narratives sit far apart, with one camp arguing the stock still offers a cushion and the other seeing the current price as broadly full.

Bull case: 16% undervalued

"Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet..."

Bear case: roughly fairly valued

"P/E ratio is currently quite high at the moment but is reflected based on projected growth..."

Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!

The Bottom Line

For Eli Lilly, the Discounted Cash Flow (DCF) intrinsic value points to meaningful upside, while earnings multiples flag the stock as overvalued versus peers and a tailored fair P/E. Broader checks lean weak, so the DCF signal sits on top of a mixed valuation picture rather than a clear across the board bargain. The split largely reflects how strongly investors are willing to price in future growth and earnings for obesity and diabetes drugs after a very large multi year move. The crux from here is whether Eli Lilly’s cash generation ultimately justifies today’s premium P/E or whether that premium settles closer to the modelled fair multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.